CGEM News and Press, Cullinan Oncology Inc. From 11/09/23

Cullinan Oncology Inc. (CGEM) is expected to report $-0.91 for Q3 2023

2023-11-08 08:48:48 ET More on Cullinan Oncology Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data Cullinan Oncology (CGEM) Investor Presentation - Slideshow Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings dat...

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial CLN-619 clinical biomarker data support mechanism of action and demonstrate monotherapy clinic...

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activit...

2023-09-11 11:57:47 ET Summary Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EGFRex20ins NSCLC, positioning it as a potential tre...

2023-08-10 12:11:29 ET Cullinan Oncology press release ( NASDAQ: CGEM ): Q2 GAAP EPS of -$0.82 beats by $0.15 . Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 For further details see: Cullinan Oncology...

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endome...

CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the...

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations PR Newswire Phase 3 trial will assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adul...

2023-06-28 09:08:05 ET Summary Cullinan is an intriguing play in the biotech sector. The company hopes to have 6 assets in clinical studies by the end of 2023. Lead asset Zipalertinib recently entered a pivotal study in EXON-20 mutated NSCLC - potentially a $1bn per annum mark...